Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Top Cited Papers
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9386), 772-776
- https://doi.org/10.1016/s0140-6736(03)14284-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosisEuropean Heart Journal, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsAmerican Heart Journal, 2000
- Improvement in Exercise Tolerance and Symptoms of Congestive Heart Failure During Treatment With Candesartan CilexetilCirculation, 1999
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) RegistryEuropean Heart Journal, 1999
- Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1996
- Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)American Heart Journal, 1996
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991